Protein kinase C, an elusive therapeutic target?
Related Experiment Video
Updated: May 16, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Daria Mochly-Rosen1, Kanad Das, Kevin V Grimes
1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305-5174, USA. mochly@stanford.edu
Abstract:
Protein kinase C (PKC) has been a tantalizing target for drug discovery ever since it was first identified as the receptor for the tumour promoter phorbol ester in 1982. Although initial therapeutic efforts focused on cancer, additional indications--including diabetic complications, heart failure, myocardial infarction, pain and bipolar disorder--were targeted as researchers developed a better understanding of the roles of eight conventional and novel PKC isozymes in health and disease. Unfortunately, both academic and pharmaceutical efforts have yet to result in the approval of a single new drug that specifically targets PKC. Why does PKC remain an elusive drug target? This Review provides a short account of some of the efforts, challenges and opportunities in developing PKC modulators to address unmet clinical needs.
Insights
Protein kinase C (PKC) remains an elusive drug target despite decades of research. This review explores the challenges and opportunities in developing novel PKC modulators for various diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Discovery
Background:
- Protein kinase C (PKC) identified in 1982 as a phorbol ester receptor.
- PKC isozymes play roles in various physiological and pathological processes.
- Therapeutic potential explored for cancer, diabetic complications, heart failure, pain, and bipolar disorder.
Purpose of the Study:
- To review the historical efforts in developing PKC modulators.
- To identify the challenges hindering PKC-targeted drug approval.
- To discuss future opportunities for PKC-based therapeutics.
Main Methods:
- Literature review of academic and pharmaceutical research on PKC.
- Analysis of therapeutic strategies and clinical trial outcomes.
- Examination of the biological roles of conventional and novel PKC isozymes.
Main Results:
- Despite extensive research, no specific PKC-targeting drug has been approved.
- Numerous PKC isozymes present complexity in drug development.
- Understanding of PKC's role in disease has expanded significantly.
Conclusions:
- PKC remains a challenging yet promising drug target.
- Overcoming development hurdles requires innovative approaches.
- Further research into PKC modulators could address unmet clinical needs.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
cAMP-dependent Protein Kinase Pathways
Amplifying Signals via Enzymatic Cascade
MAPK Signaling Cascades

